These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 30927072)

  • 1. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
    Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
    J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
    Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
    Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
    Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
    Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation.
    Pischedda F; Cirnaru MD; Ponzoni L; Sandre M; Biosa A; Carrion MP; Marin O; Morari M; Pan L; Greggio E; Bandopadhyay R; Sala M; Piccoli G
    Brain; 2021 Jun; 144(5):1509-1525. PubMed ID: 33876242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
    Pchelina SN; emel'ianov AK; Usenko TS
    Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
    Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
    Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2
    Liu X; Yu H; Wang Y; Li S; Cheng C; Al-Nusaif M; Le W
    Neurosci Bull; 2022 Oct; 38(10):1170-1182. PubMed ID: 35612787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.
    Skibinski G; Hwang V; Ando DM; Daub A; Lee AK; Ravisankar A; Modan S; Finucane MM; Shaby BA; Finkbeiner S
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1165-1170. PubMed ID: 28028237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.